What is the recommended diagnostic evaluation and evidence‑based management for peptic ulcer disease, including Helicobacter pylori testing, indications for upper endoscopy, and appropriate proton pump inhibitor‑based treatment regimens?

Peptic Ulcer Disease: Diagnostic Evaluation and Evidence-Based Management

Diagnostic Approach

All patients with suspected peptic ulcer disease should undergo Helicobacter pylori testing, and those aged >55 years or with alarm features (weight loss, progressive dysphagia, recurrent vomiting, GI bleeding, family history of gastric cancer) require upper endoscopy to exclude malignancy. 1

H. pylori Testing Strategy

For patients ≤55 years without alarm features:

• Perform non-invasive H. pylori testing first using urea breath test (sensitivity 88-95%, specificity 95-100%) or stool antigen test (sensitivity 94%, specificity 92%) 1, 2
• Stop PPIs, antibiotics, and bismuth products for at least 2 weeks before testing to avoid false-negative results 2
• Never use serology alone for treatment decisions—it cannot confirm active infection 2

For patients undergoing endoscopy:

• Obtain biopsies from both the ulcer base/edges (to exclude malignancy) and from the antrum and body (at least 2 from each site, 2-3 cm from pylorus) for H. pylori testing 2
• Place gastric body and antrum biopsies in separately labeled jars, especially important in PPI users due to proximal H. pylori migration 2
• All gastric ulcers must be biopsied to exclude adenocarcinoma 2

Indications for Upper Endoscopy

• Age >55 years with new-onset dyspepsia 1
• Any alarm features regardless of age 1
• Bleeding peptic ulcer (for diagnosis, risk stratification, and therapeutic intervention) 3
• Failed empirical therapy 1
• Gastric ulcers require repeat endoscopy at 6-8 weeks to document healing and obtain additional biopsies if not done initially 2, 4

---

H. pylori Eradication Therapy

Bismuth quadruple therapy for 14 days is the preferred first-line treatment, achieving 80-90% eradication rates even in areas with high clarithromycin and metronidazole resistance. 4

First-Line Regimen: Bismuth Quadruple Therapy

Components (all for 14 days): 4

• High-dose PPI twice daily (esomeprazole or rabeprazole 40 mg preferred—increases cure rates by 8-12% over standard PPIs) 4
• Bismuth subsalicylate 262 mg (2 tablets) four times daily
• Metronidazole 500 mg three to four times daily
• Tetracycline 500 mg four times daily

Critical optimization factors:

• Take PPI 30 minutes before meals on an empty stomach, without concomitant antacids 4
• 14-day duration is mandatory—improves eradication by ~5% compared to 7-10 day regimens 4
• Bismuth has no described resistance and overcomes metronidazole resistance through synergistic effects 4

Alternative First-Line (Only in Areas with Clarithromycin Resistance <15%)

Standard triple therapy should be abandoned when regional clarithromycin resistance exceeds 15-20%—most of North America and Europe now exceed this threshold 4

If clarithromycin resistance is documented <15%: 1, 4

• Esomeprazole or rabeprazole 40 mg twice daily
• Clarithromycin 500 mg twice daily
• Amoxicillin 1000 mg twice daily
• Duration: 14 days

When Bismuth is Unavailable

Concomitant non-bismuth quadruple therapy: 4

• High-dose PPI twice daily
• Amoxicillin 1000 mg twice daily
• Clarithromycin 500 mg twice daily
• Metronidazole 500 mg twice daily
• Duration: 14 days

---

Second-Line Therapy After First-Line Failure

After clarithromycin-based triple therapy fails, use bismuth quadruple therapy for 14 days. 4

After bismuth quadruple therapy fails, use levofloxacin triple therapy (only if no prior fluoroquinolone exposure): 4

• Esomeprazole or rabeprazole 40 mg twice daily
• Amoxicillin 1000 mg twice daily
• Levofloxacin 500 mg once daily
• Duration: 14 days

Critical pitfall: Never reuse clarithromycin or levofloxacin if they were in the failed regimen—resistance develops rapidly and eradication rates drop from 90% to 20% with resistant strains 4

---

Third-Line and Rescue Therapies

After two failed eradication attempts with confirmed patient adherence, antibiotic susceptibility testing should guide further treatment. 4

Empiric third-line options:

Rifabutin triple therapy: 4

• Rifabutin 150 mg twice daily
• Amoxicillin 1000 mg twice daily
• High-dose PPI twice daily
• Duration: 14 days

High-dose dual therapy (alternative rescue): 4

• Amoxicillin 2-3 grams daily in 3-4 divided doses
• High-dose PPI twice daily
• Duration: 14 days

---

Confirmation of Eradication

Test for eradication success at least 4 weeks after completing therapy using urea breath test or validated monoclonal stool antigen test. 4

Critical requirements:

• Discontinue PPIs at least 2 weeks before testing 4
• Never use serology to confirm eradication—antibodies persist long after successful treatment 4
• Testing is mandatory for: bleeding peptic ulcers, gastric ulcers, complicated ulcers, and gastric MALT lymphoma 4

---

Special Clinical Scenarios

Bleeding Peptic Ulcer

Start H. pylori eradication therapy immediately when oral feeding is reintroduced after stabilization—delaying treatment reduces compliance and increases loss to follow-up. 3

• All bleeding peptic ulcer patients must undergo H. pylori testing 1
• Eradication reduces rebleeding rate from 26% to near-zero 1, 3
• During active bleeding, endoscopic biopsy has a 25-55% false-negative rate—repeat testing after the acute episode if initial tests are negative 3
• High-dose IV PPI (80 mg bolus) before endoscopy does not replace the need for urgent endoscopy and does not reduce mortality 3
• Continue PPI therapy for 6-8 weeks after endoscopic hemostasis to allow mucosal healing 4

NSAID-Related Ulcers

Eradicate H. pylori before starting chronic NSAID therapy in patients with prior peptic ulcer—reduces risk of new ulcer by ~50%. 4

• Discontinue NSAIDs immediately if medically feasible 3
• For non-H. pylori ulcers (e.g., NSAID-related), PPI alone for 4-8 weeks is sufficient—antibiotics are not indicated 4
• All aspirin users with history of gastroduodenal ulcer should be tested for H. pylori 4

Gastric vs. Duodenal Ulcer Management

Gastric ulcers require repeat endoscopy at 6 weeks to confirm healing and exclude malignancy; continue PPI until healing is documented. 2, 4

Duodenal ulcers do not require prolonged PPI therapy after successful H. pylori eradication. 4

Penicillin Allergy

Bismuth quadruple therapy is the first choice in patients with penicillin allergy—it contains tetracycline, not amoxicillin. 4

Consider penicillin allergy testing after first-line failure, as most reported allergies are not true allergies 4

---

Critical Pitfalls to Avoid

• Never use standard-dose PPI once daily—high-dose twice-daily dosing is mandatory 4
• Never shorten therapy below 14 days 4
• Avoid pantoprazole—40 mg provides acid suppression equivalent to only 9 mg omeprazole 4
• Do not use levofloxacin as first-line therapy—reserve for second-line after clarithromycin failure 4
• Never repeat the same failed regimen—guarantees failure and accelerates resistance 4
• Do not test for cure earlier than 4 weeks after therapy completion 4
• Smoking roughly doubles the odds of treatment failure (OR 1.95)—advise cessation during therapy 4
• High BMI/obesity may lower gastric mucosal drug concentrations, potentially reducing efficacy 4